Skip to main content
. Author manuscript; available in PMC: 2010 Nov 30.
Published in final edited form as: J Neuroimmunol. 2009 Oct 8;216(1-2):66–75. doi: 10.1016/j.jneuroim.2009.09.009

Fig. 6.

Fig. 6

CXCL11 immunoreactivity in control or axotomized wild-type (WT) and presymptomatic mutant superoxide dismutase 1 (mSOD1) mouse facial motor nucleus 7, 14 and 30 days post-axotomy (DPA). (A) Low-power (original magnification, 100×) photomicrographs of CXCL11 immunoreactivity in control and axotomized mouse facial motor nucleus. (B) The average percent CXCL11+ FMN in the control and axotomized WT and mSOD1 mouse facial motor nucleus (±SEM). * and # denote significant differences from WT control and mSOD1 control mice at p ≤ 0.05, respectively. † denotes significant differences from WT 14 DPA mice at p ≤ 0.05.